Trevi Therapeutics (NASDAQ:TRVI – Get Free Report) was upgraded by Raymond James from an “outperform” rating to a “strong-buy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback